Show simple item record

dc.contributor.authorCheung, K.
dc.contributor.authorMa, L.
dc.contributor.authorWang, G.
dc.contributor.authorCoe, D.
dc.contributor.authorFerro, R.
dc.contributor.authorFalasca, Marco
dc.contributor.authorBuckley, C.
dc.contributor.authorMauro, C.
dc.contributor.authorMarelli-Berg, F.
dc.date.accessioned2017-01-30T12:13:39Z
dc.date.available2017-01-30T12:13:39Z
dc.date.created2015-10-29T04:10:07Z
dc.date.issued2015
dc.identifier.citationCheung, K. and Ma, L. and Wang, G. and Coe, D. and Ferro, R. and Falasca, M. and Buckley, C. et al. 2015. CD31 signals confer immune privilege to the vascular endothelium. Proceedings of the National Academy of Sciences. 112 (43): pp. E5815-E5824.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/19397
dc.identifier.doi10.1073/pnas.1509627112
dc.description.abstract

Maintenance of vascular integrity during effector immune responses occurring in tissues is a prerequisite of a healthy immune response. The mechanism whereby the vascular endothelium remains undamaged while interacting with effector immune cells migrating to the site of inflammation is largely unknown. This study shows that signals mediated by CD31, a trans-homophilic receptor expressed at high levels by the endothelium, are both necessary and sufficient to prevent inflammation-induced endothelial cell death and confer immune privilege to the vascular endothelium. We also provide proof of principle that this property can be harnessed therapeutically in pancreatic β-cell transplantation, whereby CD31 gene transfer alone endows allogeneic targets with indefinite resistance to immune attack in vivo.

dc.titleCD31 signals confer immune privilege to the vascular endothelium
dc.typeJournal Article
dcterms.source.titleProceedings of the National Academy of Sciences
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusOpen access via publisher


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record